Heart plaque showdown: combo pill vs. super statin
NCT ID NCT06767345
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares two approaches to stabilize fatty plaque in heart arteries: a moderate-dose statin plus ezetimibe versus a high-dose statin alone. Over 400 adults with coronary artery disease will be followed for a year, using advanced ultrasound to measure plaque changes. The goal is to see if the combination therapy works as well as the stronger statin, potentially offering a safer option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rosuvastatin and ezetimibe
- What this could lead to
- If successful, this could show that a moderate statin combined with ezetimibe is just as good as a high-dose statin at stabilizing artery plaque, potentially offering a gentler option for heart disease patients.
- What could go wrong
- This is a Phase 4 trial with 408 participants, so results are still limited. The study focuses on imaging changes, not directly on preventing heart attacks, and the combination therapy might not prove superior or even non-inferior to the standard high-dose statin.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS OF CORONARY ARTERY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Korea University Anam Hospital
RECRUITINGSeoul, Seoul, 02841, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Software-Guided heart procedures: a new standard for coronary care?
- Heart patients may stay active longer with coach calls and group support
- Sitting less could be a lifeline for frail hearts – a new trial tests a simple program
- Can balloon timing make or break heart artery success?
- Can we predict which heart aneurysms will grow?
- Can a higher dose of adenosine sharpen heart scans?